Cancer Immunology – News and Features

Company expanding R&D to advance its DNA delivery technology and develop proprietary DNA vaccines for cancer and chronic infectious diseases.

Data from a clinical study of DNA-based prostrate cancer demonstrated that Inovio’s DNA delivery technology enhanced the potency of the gene-based vaccine.

The study shows that human embryonic stem cells can be transformed into the pancreatic cells that produce insulin that can offer the potential to treat diabetes.

Inovio’s Executive Director will present key aspects of non-viral DNA delivery at Arrowhead Drug Delivery 2007 in San Francisco.

A new study shows that immunity to cancer stem cells may help protect people with a precancerous condition from developing the full-blown disease.

Clinical trials to be conducted in Beijing, China with renowned hematologist.

Argos Therapeutics initiates a Phase 1/2 clinical trial to test the immunologic activity and safety of its AGS-004 in HIV-infected adults.

Prominent scientists gathered in Basel to discuss new perspectives and emerging technologies across a broad range of industries.

Bellicum announces licensing agreement with Ariad for development of new cancer therapies.

Company also launches its phase I/II GNRH vaccine trial for the treatment of hormone dependant prostate cancer.